For the Inventor, By the Inventor

Enter assignee name

Yonkers, NY, United States of America

Contrafect Corporation

USPTO Granted Patents = 16

% Expired Patents = 25.0

EPO Patents = 4

Trademarks = 2

Forward Citations = 36

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Michael Wittekind (11 out of 25 patents)

Raymond Schuch (10 out of 12 patents)

Robert C Nowinski (6 out of 7 patents)

4. Adam Vigil (4 out of 5 patents)

5. Angeles Estelles (2 out of 11 patents)

6. Lawrence M Kauvar (2 out of 84 patents)

7. Jimmy Andrew Rotolo (2 out of 14 patents)

8. Han Lee (2 out of 2 patents)

9. Brent Schneider (2 out of 2 patents)

10. Simon Hoffenberg (2 out of 7 patents)

11. Assaf Raz (2 out of 3 patents)

12. Vincent A Fischetti (2 out of 85 patents)

13. Babar Khan (2 out of 2 patents)

16 patents: Sort by Forward Citations

1. 11827693 - Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy (2023-11-28),

2. 11773140 - Gram-negative lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof in human serum (2023-10-03),

3. 11524046 - Biofilm prevention, disruption and treatment with bacteriophage lysin (2022-12-13),

4. 11413334 - Lysin polypeptides active against Gram-negative bacteria (2022-08-16),

5. 11357833 - Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby (2022-06-14),

6. 11246928 - Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof (2022-02-15),

7. 10988520 - Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof (2021-04-27),

8. 10851401 - Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides (2020-12-01),

9. 10813983 - Bacteriophage lysin and antibiotic combinations against gram positive bacteria (2020-10-27),

10. 10744189 - Lysin polypeptides active against Gram-negative bacteria (2020-08-18),

11. 10639370 - Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof (2020-05-05),

12. 9889181 - Bacteriophage lysin and antibiotic combinations against gram positive bacteria (2018-02-13),

13. 9731010 - Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria (2017-08-15),

14. 9718875 - Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy (2017-08-01),

15. 9499594 - Biofilm prevention, disruption and treatment with bacteriophage lysin (2016-11-22),

CONTRAFECT CORPORATION is a clinical-stage biotechnology company focused on developing and commercializing innovative products to treat drug-resistant infectious diseases. With a unique technology platform, the company aims to address the growing global problem of antibiotic resistance. CONTRAFECT is committed to delivering novel therapies that can potentially save lives and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Contrafect Corporation

16 Patents

#10 in Yonkers, NY

#1,158 in New York

#19,874 in US

#37,722 in the World

Yonkers, NY, United States of America

Contrafect Corporation

Forward Citations = 36

13 inventors:

Michael Wittekind (11 out of 25 patents)

Raymond Schuch (10 out of 12 patents)

Robert C Nowinski (6 out of 7 patents)

4. Adam Vigil (4 out of 5 patents)

5. Angeles Estelles (2 out of 11 patents)

Please report any incorrect information to [email protected]

Loading…